Screener
Alnylam Pharmaceuticals ALNY Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net product revenues | $1,172,109 | $672,212 | $2,208,236 | $1,140,750 |
| Net revenues from collaborations | 47,165 | 61,496 | 129,240 | 160,681 |
| Royalty revenue | 71,674 | 39,981 | 120,647 | 66,447 |
| Total revenues | 1,290,948 | 773,689 | 2,458,123 | 1,367,878 |
| Operating costs and expenses: | ||||
| Cost of goods sold | 298,261 | 142,029 | 505,781 | 212,212 |
| Cost of collaborations and royalties | 190 | 924 | 3,792 | 1,782 |
| Research and development | 413,134 | 323,621 | 778,000 | 588,743 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's total revenue?
- Alnylam Pharmaceuticals (ALNY) reported total revenue of $1.29B in Q2 2026.
- How has Alnylam Pharmaceuticals's total revenue changed year-over-year?
- Alnylam Pharmaceuticals's total revenue increased by 66.9% year-over-year, from $773.69M to $1.29B.
- What is the long-term trend for Alnylam Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's total revenue has grown at a 44.8% compound annual growth rate (CAGR), from $844.29M to $3.71B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Alnylam Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude